Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?

European Journal of Surgical Oncology

Volumn 25, Issue 1, 1999, Pages 61-65

  Plastiras, D ^a   Moutzouris, G ^a   Barbatis, C ^b   Presvelos, V ^b   Petrakos, M ^a   Theodorou, Ch ^a  

^a Polycliniki Hospital   (Greece)

^b RED CROSS HOSPITAL   (Greece)

Author keywords

Bcl 2; Bladder cancer; p53; PCNA; Prognosis

Indexed keywords

CYCLINE; PARAFFIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CELL NUCLEUS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

EID: 0033082142     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1998.0601     Document Type: Article

References (22)

1. Abel P.D., Hall R.R., Williams G. Should pT1 transitional cell cancers of the bladder still be classified as superficial? Br J Urol. 62:1988;235-239.
2. Jakse G., Loidl W., Seeber G., Hofstadter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavourable tumour? J Urol. 137:1987;39-43.
3. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
4. Lane D.P. p53, guardian of the genome. Nature. 358:1992;15-16.
5. Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70:1992;923-935.
6. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1992;847-849.
7. Lotem J., Sachs L. Haematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 82:1993;1092-1096.
8. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., Reed J.C. Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
9. Bronner M., Culin C., Reed J.C., Furth E.E. bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol. 146:1994;20-26.
10. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W.K., Hsieh J., Tu S., Cambell M.L. Expression of the protooncogene bcl-2 in the prostate and association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
11. Esrig D., Elmajian D., Groshen S., Freeman J.A., Stein J.P., Chen S.C., Nichols P.W., Skinner D.G., Jones P.A., Cote R.J. Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl J Med. 331:1994;1259-1264.
12. Sarkis A.S., Dalbagni G., Gordon-Cardo C., Zhang Z., Sheinfeld J., Fair W., Herr H.H., Reuter V.E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 85:1993;53-59.
13. Sarkis A.S., Dalbagni G., Cordon-Cardo C., Melamed J., Zhang Z., Sheinfeld J., Fair W.R., Herr H.H., Reuter V.E. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 152:1994;388-392.
14. Thomas D.J., Robinson M.C., Charlton R., Wilkinson S., Shenton B.K., Neal D.E. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br J Urol. 73:1993;533-537.
15. Gardiner R.A., Walsh M.D., Allen V., Rahman S., Samaratunga MLTH, Seymour G.J., Lavin M.F. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol. 73:1994;526-532.
16. Moch H., Sauter G., Mihatsch M., Gubat F., Epper R., Waldman F. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol. 25:1994;1346-1351.
17. Nunez G., London L., Hockenbery D., Alexander M., McKearn J.P., Korsmeyer S.J. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor deprived hematopoietic cell lines. J Immunol. 144:1990;3602-3610.
18. Miyashita T., Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81:1993;151-157.
19. Shiina H., Igawa M., Urakami S., Honda S., Shirakawa H., Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J Clin Pathol. 49:1996;395-399.
20. Glick S.H., Howell L.P., White R.W.D. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol. 155:1996;1754-1757.
21. Lipponen P.K., Aaltomaa S., Eskelinen M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours. Histopathology. 28:1996;135-140.
22. Doussis I.A., Pezzella F., Lane D.P., Gatter K.C., Mason D.Y. An immunohistochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am J Clin Pathol. 99:1993;663-667.